See more : Kimco Realty Corporation (KIM-PM) Income Statement Analysis – Financial Results
Complete financial analysis of WuXi Biologics (Cayman) Inc. (2269.HK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of WuXi Biologics (Cayman) Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Telefonaktiebolaget LM Ericsson (publ) (ERIBR.HE) Income Statement Analysis – Financial Results
- Shin Nippon Air Technologies Co., Ltd. (1952.T) Income Statement Analysis – Financial Results
- Audacy, Inc. (AUD) Income Statement Analysis – Financial Results
- Pradeep Metals Limited (PRADPME.BO) Income Statement Analysis – Financial Results
- Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (603811.SS) Income Statement Analysis – Financial Results
WuXi Biologics (Cayman) Inc. (2269.HK)
About WuXi Biologics (Cayman) Inc.
WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | 17.03B | 15.27B | 10.29B | 5.61B | 3.98B | 2.53B | 1.62B | 989.03M | 557.04M | 331.85M |
Cost of Revenue | 10.21B | 8.54B | 5.46B | 3.08B | 2.32B | 1.52B | 958.27M | 599.92M | 376.32M | 208.60M |
Gross Profit | 6.83B | 6.72B | 4.83B | 2.53B | 1.66B | 1.02B | 660.56M | 389.11M | 180.72M | 123.25M |
Gross Profit Ratio | 40.08% | 44.04% | 46.93% | 45.13% | 41.64% | 40.16% | 40.80% | 39.34% | 32.44% | 37.14% |
Research & Development | 792.58M | 682.82M | 501.58M | 303.73M | 259.65M | 169.29M | 74.48M | 53.28M | 39.74M | 35.02M |
General & Administrative | 1.50B | 1.27B | 875.93M | 511.44M | 367.29M | 227.72M | 134.02M | 93.71M | 70.38M | 42.52M |
Selling & Marketing | 294.01M | 162.91M | 124.65M | 94.42M | 77.08M | 42.43M | 27.62M | 15.33M | 13.45M | 4.30M |
SG&A | 2.09B | 1.43B | 1.00B | 605.85M | 444.37M | 270.15M | 161.64M | 109.04M | 83.83M | 46.82M |
Other Expenses | 0.00 | -189.66M | -137.93M | -138.15M | -102.25M | -115.82M | -12.20M | -438.00K | -2.73M | -9.51M |
Operating Expenses | 2.88B | 1.93B | 1.36B | 771.43M | 601.77M | 323.62M | 223.92M | 161.88M | 120.84M | 72.34M |
Cost & Expenses | 13.08B | 10.47B | 6.83B | 3.85B | 2.93B | 1.84B | 1.18B | 761.80M | 497.16M | 280.93M |
Interest Income | 219.18M | 107.48M | 58.03M | 80.86M | 63.86M | 78.39M | 8.75M | 413.00K | 66.00K | 60.00K |
Interest Expense | 158.49M | 64.38M | 39.19M | 42.73M | 19.61M | 138.59M | 35.69M | 24.16M | 2.53M | 2.56M |
Depreciation & Amortization | 1.17B | 800.67M | 481.78M | 303.01M | 221.37M | 143.77M | 122.75M | 93.19M | 62.71M | 41.06M |
EBITDA | 5.50B | 6.22B | 4.51B | 2.31B | 1.37B | 881.49M | 471.39M | 319.08M | 124.94M | 93.88M |
EBITDA Ratio | 32.30% | 45.58% | 42.16% | 36.72% | 33.42% | 40.25% | 29.12% | 32.87% | 22.43% | 28.29% |
Operating Income | 3.95B | 6.16B | 3.86B | 1.76B | 1.11B | 876.43M | 348.64M | 201.54M | 62.23M | 52.82M |
Operating Income Ratio | 23.19% | 40.34% | 37.48% | 31.33% | 27.86% | 34.58% | 21.54% | 20.38% | 11.17% | 15.92% |
Total Other Income/Expenses | 224.34M | 1.02B | 805.01M | 463.73M | 69.57M | 43.58M | -146.70M | -50.05M | 10.09M | -3.81M |
Income Before Tax | 4.17B | 5.36B | 3.99B | 1.97B | 1.13B | 737.72M | 303.69M | 175.85M | 65.40M | 49.01M |
Income Before Tax Ratio | 24.50% | 35.09% | 38.81% | 35.03% | 28.28% | 29.11% | 18.76% | 17.78% | 11.74% | 14.77% |
Income Tax Expense | 603.18M | 807.87M | 484.54M | 273.07M | 116.30M | 107.26M | 51.06M | 34.75M | 20.89M | 7.03M |
Net Income | 3.40B | 4.42B | 3.39B | 1.69B | 1.01B | 630.59M | 252.63M | 141.10M | 44.51M | 41.98M |
Net Income Ratio | 19.96% | 28.95% | 32.93% | 30.09% | 25.45% | 24.88% | 15.61% | 14.27% | 7.99% | 12.65% |
EPS | 0.77 | 1.06 | 0.81 | 0.43 | 0.27 | 0.16 | 0.08 | 0.04 | 0.01 | 0.01 |
EPS Diluted | 0.78 | 1.01 | 0.77 | 0.40 | 0.25 | 0.16 | 0.07 | 0.04 | 0.01 | 0.01 |
Weighted Avg Shares Out | 4.40B | 4.17B | 4.40B | 4.21B | 4.00B | 3.94B | 3.22B | 3.40B | 3.40B | 3.40B |
Weighted Avg Shares Out (Dil) | 4.35B | 4.38B | 4.42B | 4.21B | 4.00B | 3.94B | 3.48B | 3.40B | 3.40B | 3.40B |
WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities
WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts
Source: https://incomestatements.info
Category: Stock Reports